|
WO2021055936A1
|
|
Small-molecule inhibitors for the β-catenin/b-cell lymphoma 9 protein−protein interaction
|
|
WO2021051052A1
|
|
Systems and methods to optimize and fractionize radiation for personalized radiation therapy
|
|
WO2021051066A1
|
|
Her3 pulsed dc1 therapy
|
|
WO2021051053A1
|
|
Modeling variability in radiosensitivity and tumor immune contexture to personalize radiotherapy
|
|
WO2021041617A1
|
|
Methods of enhancing car t cell therapy
|
|
WO2021035172A1
|
|
Diagnostics and methods for prognosing response to immunotherapy based on the methylation status of immune synapse gene signature
|
|
WO2021035128A1
|
|
Compositions and methods for treating chronic myelomonocytic leukemia
|
|
WO2021034774A1
|
|
Fucosylation and immune modulation in cancer
|
|
WO2021030784A1
|
|
Radiomic signature for prediciting lung cancer immunotherapy response
|
|
WO2021034684A1
|
|
Chimeric antigen receptors for treating myeloid malignancies
|
|
WO2021034689A1
|
|
Anti-cd83 chimeric antigen receptor expressing t regulatory cells
|
|
WO2021021804A1
|
|
Methods, systems, and computer-readable media for predicting a cancer patient's response to immune-based or targeted therapy
|
|
WO2021016228A1
|
|
Combination therapy for treating ras-mutant cancers
|
|
WO2021007573A1
|
|
Engineering notch ligands to enhance the anti-tumor activity of adoptively transferred t cells
|
|
WO2020263919A1
|
|
A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
|
|
WO2020252457A1
|
|
Processes and compounds for the decarboxylative amination of redox-active esters with diazirines
|
|
WO2020243458A1
|
|
Therapeutic b-cells engineered to express bispecific t cell engager antibodies
|
|
WO2020243537A1
|
|
Therapeutic t-cells with modified expression of t-bet, eomes, and c-myb transcription factors
|
|
WO2020237242A1
|
|
System and method of evaluating neural networks to segment medical images
|
|
WO2020227710A1
|
|
Systems and methods for slide image alignment
|
